MX370721B - Compuestos y composiciones novedosas para atacar las células madre del cáncer. - Google Patents
Compuestos y composiciones novedosas para atacar las células madre del cáncer.Info
- Publication number
- MX370721B MX370721B MX2012010434A MX2012010434A MX370721B MX 370721 B MX370721 B MX 370721B MX 2012010434 A MX2012010434 A MX 2012010434A MX 2012010434 A MX2012010434 A MX 2012010434A MX 370721 B MX370721 B MX 370721B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- stem cells
- novel compounds
- cancer stem
- targeting cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
Abstract
La invención proporciona compuestos de naftofurano, polimorfos de compuestos de naftofurano, compuestos de naftofurano en forma de partículas, composiciones purificadas que contienen uno o más compuestos de naftofurano, composiciones purificadas que contienen uno o más compuestos de naftofurano en forma de partículas, métodos para producir dichos compuestos de naftofurano, polimorfos, composiciones purificadas y/o formas de partículas y métodos para el uso de estos compuestos, polimorfos, composiciones purificadas y/o formas de partículas de naftofurano para tratar sujetos en necesidad de lo mismo.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31589010P | 2010-03-19 | 2010-03-19 | |
US31588610P | 2010-03-19 | 2010-03-19 | |
US32581410P | 2010-04-19 | 2010-04-19 | |
PCT/US2011/029281 WO2011116398A1 (en) | 2010-03-19 | 2011-03-21 | Novel compounds and compositions for targeting cancer stem cells |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012010434A MX2012010434A (es) | 2013-01-29 |
MX370721B true MX370721B (es) | 2019-12-20 |
Family
ID=47678419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012010434A MX370721B (es) | 2010-03-19 | 2011-03-21 | Compuestos y composiciones novedosas para atacar las células madre del cáncer. |
Country Status (15)
Country | Link |
---|---|
US (4) | US9084766B2 (es) |
EP (1) | EP2547334B1 (es) |
JP (1) | JP5602935B2 (es) |
KR (2) | KR101714819B1 (es) |
CN (3) | CN103002890A (es) |
AU (2) | AU2011227022C1 (es) |
BR (2) | BR122021025776B1 (es) |
CA (2) | CA2946899C (es) |
DK (1) | DK2547334T3 (es) |
ES (1) | ES2659541T3 (es) |
MX (1) | MX370721B (es) |
NZ (1) | NZ602328A (es) |
RU (1) | RU2571661C2 (es) |
SG (1) | SG184063A1 (es) |
WO (1) | WO2011116398A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8877803B2 (en) | 2007-09-10 | 2014-11-04 | Boston Biomedical, Inc. | Stat3 pathway inhibitors and cancer stem cell inhibitors |
CN103002890A (zh) * | 2010-03-19 | 2013-03-27 | 波士顿生物医学公司 | 靶向癌症干细胞的新的化合物和组合物 |
CN104016951B (zh) * | 2010-03-19 | 2016-07-13 | 北京强新生物科技有限公司 | 靶向癌症干细胞的化合物和组合物 |
BR112015025347A2 (pt) * | 2013-04-09 | 2017-07-18 | Boston Biomedical Inc | 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer |
CN109867647A (zh) | 2014-02-07 | 2019-06-11 | 北京强新生物科技有限公司 | 3-取代的羰基萘并[2,3-b]呋喃衍生物或其药学上可接受的盐 |
AU2015272560B2 (en) * | 2014-06-09 | 2019-02-14 | Kyoto Pharmaceutical Industries, Ltd. | Novel anticancer agent |
BR112017022269A2 (pt) | 2015-04-17 | 2018-07-10 | Boston Biomedical Inc | métodos para tratar câncer |
EA201792287A1 (ru) | 2015-04-17 | 2018-03-30 | Бостон Биомедикал, Инк. | Способы лечения рака |
EP3302462A1 (en) * | 2015-06-03 | 2018-04-11 | Boston Biomedical, Inc. | Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer |
US10329267B2 (en) | 2015-07-17 | 2019-06-25 | Sumitomo Dainippon Pharma Co., Ltd. | Method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione |
WO2017079864A1 (en) * | 2015-11-12 | 2017-05-18 | Hangzhou Yier Biotech Co., Ltd. | Treatment of cancers related to chronically active ras |
US20190076392A1 (en) | 2016-01-20 | 2019-03-14 | Boston Biomedical, Inc. | Methods for treating cancer |
WO2017160978A1 (en) | 2016-03-15 | 2017-09-21 | Boston Biomedical, Inc. | Cell cultures and use thereof |
CA3029596A1 (en) | 2016-06-28 | 2018-01-04 | Boston Biomedical, Inc. | Methods for treating cancer |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
US11299469B2 (en) | 2016-11-29 | 2022-04-12 | Sumitomo Dainippon Pharma Oncology, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
CA3058162A1 (en) | 2017-03-30 | 2018-10-04 | Boston Biomedical, Inc. | Compositions for treating and/or preventing cancer |
CA3062656A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
US20210393571A1 (en) | 2018-10-12 | 2021-12-23 | 1Globe Biomedical Co., Ltd. | New Combination Solution for Treating Chemotherapy Refractory Cancer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1049490A1 (ru) * | 1982-05-18 | 1983-10-23 | Ордена Трудового Красного Знамени Институт Химии Ан Мсср | (3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции |
JPH1121284A (ja) | 1997-06-30 | 1999-01-26 | Kotobuki:Kk | フラノナフトキノン誘導体及びこれを含有する医薬 |
AU2003275056A1 (en) * | 2002-09-17 | 2004-04-08 | Arqule, Inc. | Novel lapacho compounds and methods of use thereof |
US20070238770A1 (en) * | 2006-04-05 | 2007-10-11 | Bristol-Myers Squibb Company | Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations |
US8877803B2 (en) * | 2007-09-10 | 2014-11-04 | Boston Biomedical, Inc. | Stat3 pathway inhibitors and cancer stem cell inhibitors |
US20100298402A1 (en) | 2007-11-06 | 2010-11-25 | Orchid Research Laboratories Limited | Stilbene derivatives as pstat3/il-6 inhibitors |
CN103002890A (zh) * | 2010-03-19 | 2013-03-27 | 波士顿生物医学公司 | 靶向癌症干细胞的新的化合物和组合物 |
-
2011
- 2011-03-21 CN CN2011800231072A patent/CN103002890A/zh active Pending
- 2011-03-21 AU AU2011227022A patent/AU2011227022C1/en active Active
- 2011-03-21 SG SG2012068102A patent/SG184063A1/en unknown
- 2011-03-21 CN CN201710613671.9A patent/CN107375260B/zh active Active
- 2011-03-21 CA CA2946899A patent/CA2946899C/en not_active Expired - Fee Related
- 2011-03-21 BR BR122021025776-0A patent/BR122021025776B1/pt active IP Right Grant
- 2011-03-21 KR KR1020127027267A patent/KR101714819B1/ko active IP Right Grant
- 2011-03-21 BR BR112012023661-0A patent/BR112012023661A2/pt not_active Application Discontinuation
- 2011-03-21 CN CN201710665153.1A patent/CN107721958B/zh active Active
- 2011-03-21 US US13/634,676 patent/US9084766B2/en not_active Expired - Fee Related
- 2011-03-21 KR KR1020167032280A patent/KR101908208B1/ko active IP Right Grant
- 2011-03-21 CA CA2793526A patent/CA2793526C/en not_active Expired - Fee Related
- 2011-03-21 RU RU2012144421/04A patent/RU2571661C2/ru active
- 2011-03-21 DK DK11757134.9T patent/DK2547334T3/en active
- 2011-03-21 MX MX2012010434A patent/MX370721B/es active IP Right Grant
- 2011-03-21 NZ NZ602328A patent/NZ602328A/en unknown
- 2011-03-21 WO PCT/US2011/029281 patent/WO2011116398A1/en active Application Filing
- 2011-03-21 EP EP11757134.9A patent/EP2547334B1/en active Active
- 2011-03-21 ES ES11757134.9T patent/ES2659541T3/es active Active
- 2011-03-21 JP JP2013500246A patent/JP5602935B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-10 US US14/642,931 patent/US9381184B2/en not_active Expired - Fee Related
-
2016
- 2016-02-15 AU AU2016200953A patent/AU2016200953B2/en active Active
- 2016-05-31 US US15/169,315 patent/US20160271099A1/en not_active Abandoned
-
2018
- 2018-01-05 US US15/863,132 patent/US20180193303A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX370721B (es) | Compuestos y composiciones novedosas para atacar las células madre del cáncer. | |
PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
MY157124A (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
IN2014KN02601A (es) | ||
PH12014501229A1 (en) | Antibody-drug conjugates and related compounds, compositions, and methods | |
MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
PH12017500864A1 (en) | Anti-notch1 antibodies | |
IN2012DN03883A (es) | ||
WO2011082273A3 (en) | Substituted pyrrolo-aminopyrimidine compounds | |
MX2016002571A (es) | Regulador de ph de transduccion. | |
WO2011082267A8 (en) | Substituted triazolo-pyrazine compounds | |
MY184101A (en) | Indoles | |
IN2012DN02081A (es) | ||
MY171375A (en) | Substituted tricyclic compounds as fgfr inhibitors | |
MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
MX2011007930A (es) | Conjugados de insulina cristalina. | |
MX344530B (es) | Compuestos de benceno substituido. | |
WO2011082266A3 (en) | Substituted heterocyclic compounds | |
MX2011014019A (es) | Derivados de diazahomoadamantano y sus metodos de uso. | |
MX2015014181A (es) | 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer. | |
WO2011123678A3 (en) | Substituted benzo-pyrido-triazolo-diazepine compounds | |
WO2011129936A3 (en) | Compositions and methods for the prevention and treatment of cancer | |
WO2011082268A3 (en) | Substituted naphthalenyl-pyrimidine compounds | |
MX357166B (es) | Anticuerpos que se unen a notum pectinacetilesterasa. | |
MX2015005734A (es) | Metodos de tratamiento de enfermedades hepaticas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |